Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade

Weilei Hu, Guosheng Wang, Yian Wang, Matthew J. Riese, Ming You

    Research output: Contribution to journalReview articlepeer-review

    22 Scopus citations


    Immunotherapy with monoclonal antibodies targeting immune checkpoint molecules, including programmed death-1 (PD-1), PD ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen (CTLA)-4, has become prominent in the treatment of many types of cancer. However, a significant number of patients treated with immune checkpoint inhibitors (ICIs) develop immune-related adverse events (irAEs). irAEs can affect any organ system, and although most are clinically manageable, irAEs can result in mortality or long-term morbidity. Factors that can predict irAEs remain elusive. Understanding the etiology of ICI-induced irAEs and ways to limit these adverse events are needed. In this review, we provide basic science and clinical insights on the mechanisms responsible for ICI efficacy and ICI-induced irAEs. We further provide insights into approaches that may uncouple irAEs from the ability of ICIs to kill tumor cells.

    Original languageEnglish (US)
    Article number101580
    Issue number10
    StatePublished - Oct 23 2020


    • Cancer
    • Clinical Medicine
    • Immunology

    ASJC Scopus subject areas

    • General


    Dive into the research topics of 'Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade'. Together they form a unique fingerprint.

    Cite this